South Africa is advancing HIV research using MGI’s sequencing tools to study "HIV elite controllers" - A rare group of individuals whose immune systems can suppress infection. Scientists from the SAMRC and UKZN are revealing the answer to the natural control of HIV infection leading to new therapies and improved health outcomes.

MGI and Predica collaborate on RNA sequencing and NGS to advance precision medicine in oncology, enabling early cancer detection and personalized treatments.

Explore the impact of TB and HIV co-infection and the latest advancements in combating drug resistance. Discover how MGI's ATOPlex platform and HIV-1 drug resistance sequencing products revolutionize detection and analysis, empowering global public health efforts.

MGI has announced a collaboration with SeqOne, a leading provider of AI-driven genomic decision support software, to develop and validate comprehensive genomic analysis solutions tailored to Human Genetics and Pathology labs worldwide.

MGI opens its new European headquarters in Berlin, featuring advanced labs, a Customer Experience Center, and showcasing the latest life science innovations and multi-omics tools.

MGI Tech unveils Q40 quality data for DNBSEQ with StandardMPS 2.0 Chemistry and launches DNBelab C-TaiM 4 Single-Cell Droplet Generator at ESHG 2024, showcasing major innovations.